title: From the bench to the bed side: PI3K pathway inhibitors in clinical development.
abstract: A number of intracellular kinase components of the PI3K/Akt/mTOR pathway have been targeted over the past few years, leading to a new generation of anticancer agents that effectively and specifically disrupt this pathway in tumor cells. Here, progress in the identification and clinical evaluation of compounds designed to modulate the enzymatic activity of PI3K, Akt, mTOR, and Hsp90 is reviewed.
authors.affiliation: Oncology Drug Discovery, Novartis Institutes for Biomedical Research, Vitry-sur-Seine Cedex, France.
authors.forename: Saveur-Michel
authors.initials: SM
authors.lastname: Maira
authors.forename: Peter
authors.initials: P
authors.lastname: Finan
authors.forename: Carlos
authors.initials: C
authors.lastname: Garcia-Echeverria
mesh_terms: D000818:Animals; D001168:Arthritis / Q000188:drug therapy; D055808:Drug Discovery; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008171:Lung Diseases / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D018841:HSP90 Heat-Shock Proteins; D007527:Isoenzymes; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases